Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass
Isabelle Gennero(Centre de Physiopathologie de Toulouse-Purpan), Jean‐Pierre Salles, Laurence Vico(Inserm), Marianne Mus(Inserm), Jackie Rue(Université Toulouse III - Paul Sabatier), Richard O. C. Oreffo(University of Southampton), Philippe Bourin(Établissement Français du Sang), Danielle Laurencin(École Nationale Supérieure de Chimie de Montpellier), Sara Laurencin‐Dalicieux(Université Toulouse III - Paul Sabatier), Nicolas Beton(Inserm), G Brunel(Université Toulouse III - Paul Sabatier), F. Conte-Auriol(Hôpital Purpan), Nicole Malet(Université Toulouse III - Paul Sabatier), Jerold Chun(Sanford Burnham Prebys Medical Discovery Institute), Akira Tokumura(Tokushima University), Fabienne Briand‐Mésange(Centre de Physiopathologie de Toulouse-Purpan)
Cited by 74
Related Papers
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k
Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain
|Science|2016|1.1k
LPA Receptors: Subtypes and Biological Actions
|The Annual Review of Pharmacology and Toxicology|2010|851
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
|Nature Medicine|2007|820
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
|Clinical Neuropharmacology|2010|794